Literature DB >> 27200638

The Impact of Long-Term Clinical Evidence on Cost-Effectiveness of Exenatide Once Weekly (Bydureon®) Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus (T2dm) From A Uk Nhs Perspective.

M Charokopou1, H Vioix2, B G Verheggen1, T Bratt2, D Franks2.   

Abstract

Entities:  

Year:  2014        PMID： 27200638     DOI： 10.1016/j.jval.2014.08.689

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  1 in total

1.  Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.

Authors:  Charalampos Tzanetakos; Alexandra Bargiota; Georgia Kourlaba; George Gourzoulidis; Nikos Maniadakis
Journal:  Clin Drug Investig       Date:  2018-01       Impact factor: 2.859
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.